• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience.新辅助放化疗后延迟手术切除对局部晚期直肠腺癌临床结局有影响吗?:单机构经验
Am J Clin Oncol. 2018 Feb;41(2):140-146. doi: 10.1097/COC.0000000000000248.
2
Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.与新辅助长疗程放化疗相比,术前序贯短疗程放疗联合FOLFOX化疗改善直肠癌患者的转移和无病生存率:配对分析结果
Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):417-426. doi: 10.1016/j.ijrobp.2017.05.048. Epub 2017 Jun 6.
3
Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery.神经周围浸润可预测接受新辅助放化疗和手术治疗的局部晚期直肠癌发生远处转移的情况。
Am J Clin Oncol. 2017 Dec;40(6):561-568. doi: 10.1097/COC.0000000000000214.
4
Long-term Oncologic Outcomes After Neoadjuvant Chemoradiation Followed by Intersphincteric Resection With Coloanal Anastomosis for Locally Advanced Low Rectal Cancer.局部晚期低位直肠癌新辅助放化疗后经肛门内括约肌间切除术行结肠肛管吻合术的长期肿瘤学结果。
Dis Colon Rectum. 2019 Apr;62(4):408-416. doi: 10.1097/DCR.0000000000001321.
5
Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.卡培他滨新辅助放化疗治疗年龄≥70 岁局部晚期直肠癌患者的耐受性、安全性和结局。
Clin Colorectal Cancer. 2018 Sep;17(3):179-186. doi: 10.1016/j.clcc.2018.03.004. Epub 2018 Mar 8.
6
Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers.局部晚期直肠癌术前放化疗后的最佳手术时间
Ann Surg. 2008 Aug;248(2):243-51. doi: 10.1097/SLA.0b013e31817fc2a0.
7
Adjuvant Chemotherapy Is Associated With Improved Overall Survival in Locally Advanced Rectal Cancer After Achievement of a Pathologic Complete Response to Chemoradiation.辅助化疗与局部晚期直肠癌在达到放化疗病理完全缓解后的总生存改善相关。
Clin Colorectal Cancer. 2017 Dec;16(4):300-307. doi: 10.1016/j.clcc.2017.03.005. Epub 2017 Mar 18.
8
Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.新辅助放化疗与根治性放化疗治疗局部晚期食管癌:结局和失败模式。
Strahlenther Onkol. 2018 Feb;194(2):116-124. doi: 10.1007/s00066-017-1211-0. Epub 2017 Sep 15.
9
Optimal Timing to Surgery after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.局部晚期直肠癌新辅助放化疗后手术的最佳时机
J Am Coll Surg. 2016 Apr;222(4):367-74. doi: 10.1016/j.jamcollsurg.2015.12.017. Epub 2016 Jan 20.
10
Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer.新辅助放化疗后病理缓解对病理 III 期直肠癌预后的影响。
Ann Surg. 2019 Jun;269(6):1117-1123. doi: 10.1097/SLA.0000000000002719.

引用本文的文献

1
Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses.新辅助放化疗与手术之间的间隔时间延长对局部晚期直肠癌的临床结局有益吗?一项系统评价和荟萃分析。
Int J Colorectal Dis. 2022 Apr;37(4):855-868. doi: 10.1007/s00384-022-04122-w. Epub 2022 Mar 12.
2
Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer.TLR9 激活和抗 OX40 抗体的新辅助瘤内免疫疗法根除转移性癌症。
Cancer Res. 2022 Apr 1;82(7):1396-1408. doi: 10.1158/0008-5472.CAN-21-1382.
3
Optimal interval to surgery after chemoradiotherapy in rectal cancer: A protocol for systematic review and network meta-analysis.直肠癌放化疗后手术的最佳间隔时间:一项系统评价和网状Meta分析方案
Medicine (Baltimore). 2019 Nov;98(45):e17669. doi: 10.1097/MD.0000000000017669.

本文引用的文献

1
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.术前(放)化疗和全直肠系膜切除术治疗的直肠癌患者的辅助化疗:荷兰结直肠肿瘤学组(DCCG)的一项随机 III 期试验。
Ann Oncol. 2015 Apr;26(4):696-701. doi: 10.1093/annonc/mdu560. Epub 2014 Dec 5.
2
No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT).新辅助放化疗后辅助氟尿嘧啶亚叶酸钙化疗对局部晚期直肠癌(LARC)无益处:一项随机试验(I-CNR-RT)的长期结果
Radiother Oncol. 2014 Nov;113(2):223-9. doi: 10.1016/j.radonc.2014.10.006. Epub 2014 Nov 14.
3
Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.文献标题:新辅助放化疗后局部进展期直肠癌随机 III 期临床试验结果,术后辅助卡培他滨加奥沙利铂(XELOX)与对照组比较 **解析**:这是一个医学文献的标题,其中包含了一些医学术语。在翻译时,需要注意保留关键词,如“Chronicle”(文献标题)、“randomised phase III trial”(随机 III 期临床试验)、“locally advanced rectal cancer”(局部进展期直肠癌)、“neoadjuvant chemoradiation”(新辅助放化疗)、“adjuvant capecitabine plus oxaliplatin”(术后辅助卡培他滨加奥沙利铂)、“XELOX”(药物名称)等。同时,还需要注意一些词汇的翻译,如“randomise”(随机化)、“postoperative”(术后的)等。
Ann Oncol. 2014 Jul;25(7):1356-1362. doi: 10.1093/annonc/mdu147. Epub 2014 Apr 8.
4
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.术前放化疗后氟尿嘧啶为基础的辅助化疗治疗直肠癌:EORTC 22921 随机研究的长期结果。
Lancet Oncol. 2014 Feb;15(2):184-90. doi: 10.1016/S1470-2045(13)70599-0. Epub 2014 Jan 17.
5
Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.直肠癌新辅助放化疗与手术的最佳时间间隔。
Br J Surg. 2013 Jun;100(7):933-9. doi: 10.1002/bjs.9112. Epub 2013 Mar 27.
6
Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy.新辅助治疗后完全临床缓解的直肠癌的非手术治疗。
Ann Surg. 2012 Dec;256(6):965-72. doi: 10.1097/SLA.0b013e3182759f1c.
7
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.局部进展期直肠癌术前与术后放化疗的比较:中位随访 11 年后德国 CAO/ARO/AIO-94 随机 III 期临床试验结果。
J Clin Oncol. 2012 Jun 1;30(16):1926-33. doi: 10.1200/JCO.2011.40.1836. Epub 2012 Apr 23.
8
Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.新辅助放化疗与 TME 之间间隔时间对局部进展期直肠癌病理反应和肿瘤学结局的影响。
Ann Surg Oncol. 2012 Sep;19(9):2833-41. doi: 10.1245/s10434-012-2327-1. Epub 2012 Mar 27.
9
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.系统评价和 meta 分析:新辅助放化疗治疗直肠癌后病理完全缓解的结局。
Br J Surg. 2012 Jul;99(7):918-28. doi: 10.1002/bjs.8702. Epub 2012 Feb 23.
10
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.直肠癌放化疗后临床完全缓解者的观望策略。
J Clin Oncol. 2011 Dec 10;29(35):4633-40. doi: 10.1200/JCO.2011.37.7176. Epub 2011 Nov 7.

新辅助放化疗后延迟手术切除对局部晚期直肠腺癌临床结局有影响吗?:单机构经验

Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience.

作者信息

Nguyen Phuong, Wuthrick Evan, Chablani Priyanka, Robinson Andrew, Simmons Luke, Wu Christina, Arnold Mark, Harzman Alan E, Husain Syed, Schmidt Carl, Abdel-Misih Sherif, Bekaii-Saab Tanios, Chakravarti Arnab, Williams Terence M

机构信息

Departments of Radiation Oncology.

Internal Medicine, Division of Medical Oncology.

出版信息

Am J Clin Oncol. 2018 Feb;41(2):140-146. doi: 10.1097/COC.0000000000000248.

DOI:10.1097/COC.0000000000000248
PMID:26535992
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4860166/
Abstract

OBJECTIVES

Surgical resection for locally advanced rectal adenocarcinoma commonly occurs 6 to 10 weeks after completion of neoadjuvant chemoradiation (nCRT). We sought to determine the optimal timing of surgery related to the pathologic complete response rate and survival endpoints.

METHODS

The study is a retrospective analysis of 92 patients treated with nCRT followed by surgery from 2004 to 2011 at our institution. Univariate and multivariate analyses were performed to assess the impact of timing of surgery on locoregional control, distant failure (DF), disease-free survival, and overall survival (OS).

RESULTS

Time-to-surgery was ≤8 weeks (group A) in 72% (median 6.1 wk) and >8 weeks (group B) in 28% (median 8.9 wk) of patients. No significant differences in patient characteristics, locoregional control, or pathologic complete response rates were noted between the groups. Univariate analysis revealed that group B had significantly shorter time to DF (group B, median 33 mo; group A, median not reached, P=0.047) and shorter OS compared with group A (group B, median 52 mo; group A, median not reached, P=0.03). Multivariate analysis revealed that increased time-to-surgery showed a significant increase in DF (HR=2.96, P=0.02) and trends toward worse OS (HR=2.81, P=0.108) and disease-free survival (HR=2.08, P=0.098).

CONCLUSIONS

We found that delaying surgical resection longer than 8 weeks after nCRT was associated with an increased risk of DF. This study, in combination with a recent larger study, questions the recent trend in promoting surgical delay beyond the traditional 6 to 10 weeks. Larger, prospective databases or randomized studies may better clarify surgical timing following nCRT in rectal adenocarcinoma.

摘要

目的

局部晚期直肠腺癌的手术切除通常在新辅助放化疗(nCRT)完成后6至10周进行。我们试图确定与病理完全缓解率和生存终点相关的最佳手术时机。

方法

本研究是对2004年至2011年在我院接受nCRT后手术治疗的92例患者进行的回顾性分析。进行单因素和多因素分析以评估手术时机对局部区域控制、远处转移(DF)、无病生存期和总生存期(OS)的影响。

结果

72%的患者手术时间≤8周(A组,中位时间6.1周),28%的患者手术时间>8周(B组,中位时间8.9周)。两组患者的特征、局部区域控制或病理完全缓解率无显著差异。单因素分析显示,B组至DF的时间显著短于A组(B组,中位时间33个月;A组,未达到中位时间,P=0.047),且OS短于A组(B组,中位时间52个月;A组,未达到中位时间,P=0.03)。多因素分析显示,手术时间延长与DF显著增加(HR=2.96,P=0.02)以及OS(HR=2.81,P=0.108)和无病生存期(HR=2.08,P=0.098)恶化的趋势相关。

结论

我们发现nCRT后手术切除延迟超过8周与DF风险增加相关。本研究与近期一项更大规模的研究相结合,对近期将手术延迟超过传统的6至10周的趋势提出了质疑。更大规模的前瞻性数据库或随机研究可能会更好地阐明直肠腺癌nCRT后的手术时机。